Related references
Note: Only part of the references are listed.PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-151
Kyung Hwan Kim et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies
Leander Huyghe et al.
EMBO MOLECULAR MEDICINE (2020)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Meenu Sharma et al.
NATURE COMMUNICATIONS (2020)
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
Jean-Christophe Beltra et al.
IMMUNITY (2020)
Charting the Roadmap of T Cell Exhaustion
Talyn Chu et al.
IMMUNITY (2020)
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+T Cell Function and Anti-tumor Immunity
Shanling Shen et al.
FRONTIERS IN IMMUNOLOGY (2020)
CD8+ T cell states in human cancer: insights from single-cell analysis
Anne M. Van der Leun et al.
NATURE REVIEWS CANCER (2020)
Cytokines in the Treatment of Cancer
Kevin C. Conlon et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C. Miller et al.
NATURE IMMUNOLOGY (2019)
Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Dario Neri
CANCER IMMUNOLOGY RESEARCH (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy
Noor Momin et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
William H. Hudson et al.
IMMUNITY (2019)
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva et al.
NATURE (2019)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
Guoying Zhou et al.
ONCOIMMUNOLOGY (2018)
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2018)
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
Guoying Zhou et al.
GASTROENTEROLOGY (2017)
The potential and promise of IL-15 in immuno-oncogenic therapies
Tanya O. Robinson et al.
IMMUNOLOGY LETTERS (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas et al.
SEMINARS IN ONCOLOGY (2017)
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
Rodrigo Vazquez-Lombardi et al.
NATURE COMMUNICATIONS (2017)
Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers
Ignacio Moraga et al.
ELIFE (2017)
IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities
Sigrid Dubois et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy
Zahra Valedkarimi et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy
Sarita M. Fernandez-Poma et al.
CANCER RESEARCH (2017)
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Peter R. Rhode et al.
CANCER IMMUNOLOGY RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity
Sarah L. Pogue et al.
PLOS ONE (2016)
Insights into Cytokine-Receptor Interactions from Cytokine Engineering
Jamie B. Spangler et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Tumor-Infiltrating Lymphocytes Clinical Experience
Michal J. Besser et al.
CANCER JOURNAL (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Alice Tzeng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
Thomas A. Waldmann
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety
Patricia A. Young et al.
SEMINARS IN ONCOLOGY (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15
Aaron M. Ring et al.
NATURE IMMUNOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Cutting Edge: FcR-Like 6 Is an MHC Class II Receptor
Daniel M. Schreeder et al.
JOURNAL OF IMMUNOLOGY (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Novel Human Interleukin-15 Agonists
Xiaoyun Zhu et al.
JOURNAL OF IMMUNOLOGY (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1
M Hezareh et al.
JOURNAL OF VIROLOGY (2001)
Guidelines for the safe administration of high-dose interleukin-2
DJ Schwartzentruber
JOURNAL OF IMMUNOTHERAPY (2001)
Share Paper
